Global Celecoxib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Celecoxib Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Celecoxib capsules (patent brand nameCELEBREX), is a new generation of non-steroidal anti-inflammatory and analgesic drugs, mainly through the selective inhibition of coX-2 (COX-2) to inhibit the production of prostaglandins, achieve anti-inflammatory and analgesic effects.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Celecoxib report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Celecoxib market is projected to reach US$ 2250.6 million in 2034, increasing from US$ 1271.3 million in 2022, with the CAGR of 8.4% during the period of 2024 to 2034. Demand from Rheumatoid arthritis and osteoarthritis are the major drivers for the industry.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Celecoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
Segment by Type
50mg
100mg
200mg
400mg
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Celecoxib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Celecoxib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Celecoxib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Celecoxib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Celecoxib introduction, etc. Celecoxib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Celecoxib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
The drug is used to relieve symptoms and signs of osteoarthritis and rheumatoid arthritis in adults and has fewer gastrointestinal side effects than traditional non-steroidal anti-inflammatory drugs.
Celecoxib report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Celecoxib market is projected to reach US$ 2250.6 million in 2034, increasing from US$ 1271.3 million in 2022, with the CAGR of 8.4% during the period of 2024 to 2034. Demand from Rheumatoid arthritis and osteoarthritis are the major drivers for the industry.
Data show that more than 400 million people worldwide are currently affected by joint diseases.
The prevalence of osteoarthritis is 17 percent among people aged 40, 62 percent among people over 60 and 80 percent among people over 75.
The number of patients with arthritis in mainland China is more than 10% of the total population, well over 100 million, and the incidence of arthritis increases with age, and the number of patients is still increasing.
At present, the burden of chronic diseases will increase by 40% due to the aging of the population.
As the population ages, anti-inflammatory and anti-rheumatic drugs will enter a phase of rapid growth.
Globally, whether prescription drugs or non-prescription drugs, Xibu is widely used in clinical practice.
At present, the best seller in the international market is Celixib. Celixib market will continue to grow steadily in the next few years.
At present, the global Celecoxib market is basically occupied by Pfizer, which has formed an oligopoly.
It accounted for 63.39% of the global market in 2019.
As of 2019, China relies entirely on Pfizer for celecoxib imports.
Since 2020, some domestic drug companies have been gradually approved by FDA and CFDA. The introduction of celecoxib generic drugs by local companies will break the monopoly of import.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Celecoxib market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer Inc
Teva
Mylan
Apotex
Lupin
Hengrui Medicine
Segment by Type
50mg
100mg
200mg
400mg
Segment by Application
Rheumatoid arthritis
osteoarthritis
Acute pain
Musculoskeletal pain
Other diseases
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Celecoxib market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Celecoxib, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Celecoxib industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Celecoxib in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Celecoxib introduction, etc. Celecoxib Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Celecoxib market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices